Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis
生物工程新型治疗性蛋白质复合物可最大程度地减少医疗设备引起的溶血的影响
基本信息
- 批准号:10380296
- 负责人:
- 金额:$ 70.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAffinityAnimal ModelAnimalsAttenuatedBindingBinding ProteinsBinding SitesBiological AssayBiological MarkersBiomedical EngineeringBlood CirculationBrainCardiacCardiac OutputCardiac Surgery proceduresCardiopulmonary BypassCellsCessation of lifeChemicalsClinicalComplexComplicationCytolysisDataDimerizationDoseDrug or chemical Tissue DistributionEffectivenessEngineeringErythrocytesExtracorporeal Membrane OxygenationFractionationFunctional disorderGoalsHamstersHaptoglobinsHealth Care CostsHeartHemeHeme IronHemeproteinsHemoglobinHemoglobin concentration resultHemolysisHemopexinHospitalizationHourHumanIn VitroIndividualInjury to KidneyIntestinesIronKidneyKineticsLeadLength of StayLigandsLungMedicalMedical DeviceMethodsMicrovascular PermeabilityModelingMonitorMorbidity - disease rateOperative Surgical ProceduresOrganOutcomePaste substancePatientsPlasmaProceduresProcessProteinsProteolysisPublic HealthPumpRattusRenal functionRiskSamplingSecureSelf-Help DevicesSeveritiesSupportive careSystemTestingTherapeuticTherapeutic InterventionTherapeutic UsesToxic effectToxinTransferrinUrineVentricularapohemoglobinbaseblood pumpcell injuryclinically relevantcostcost estimatedesigndimerexperiencehaptoglobin-hemoglobin complexheart functionheme ahemodynamicsimprovedin vivoindividual patientinstrumentlarge scale productionlung injurymacrophagemonocytemortalitymortality risknovelnovel therapeuticsorgan injurypreventprospectiveprotein complexproteostasispulmonary functionresponseurinary
项目摘要
PROJECT SUMMARY
Cost estimates for CNS, pulmonary, cardiac, and renal complications following medical assist devices
requiring blood pumps, for example on pump cardiopulmonary bypass (CPB) is estimated at $80 million per
individual states in the US over a ten-year period. Because of the need for extended CPB (> 4hours) use in
complex surgeries, hemolysis, and the subsequent release of hemoglobin (Hb) into the circulation – which is
known to be multi-organ toxic and vasoactive – is a relevant contributor to more intensive management of
patients. To date, no effective strategy to remove toxic by-products of Hb are available. The burden caused
by kidney injury alone accounts for approximately $9 billion/year, 300,000 deaths/year and an average
increase in hospital stay of 3.5 days/patient This project focuses on understanding the contribution of
hemolysis, Hb and heme associated with secondary end organ injury following extended on pump
cardiopulmonary bypass (typically lasting up to 4 hours). To understand medical device related red blood cell
lysis in this setting, we propose a strategy that is focused on sequentially understanding the contributions of
Hb and heme and a therapeutic strategy to attenuate the end organ pathophysiology of these toxins. We will
prospectively determine the levels of Hb, heme and iron as well as the concentrations of each toxin in
plasma and urine of cardiac surgery patients. Simultaneously we will determine the concentrations of
Hb, heme and iron binding and clearance proteins, haptoglobin, hemopexin and transferrin, respectively.
Further we will determine plasma and urinary markers of end organ injury. We will use this data to construct
a biokinetic model that determines the limits of Hb toxin concentrations that associate with end organ injury
markers. The goal of this effort will be to define the need and timing for therapeutic interventions. To this
end we have bioengineered a novel Hb, heme and protein scavenger based on our extensive experience
with studying Hb toxicity. The novel protein construct is prepared by generating apo-Hb in multi-step process,
while simultaneously isolating haptoglobin from Cohn fractionation paste IV. Finally, the two proteins are
complexed and further purified to generate the apo-Hb-haptoglobin complex. This novel protein construct
binds heme in high heme exposure states, secures iron in the heme ligand and safely clears the complex to
monocytes and macrophages. Alternatively, in high Hb exposures apo-Hb exchanges binding sites on
haptoglobin clearing Hb dimers to monocytes and macrophages, while released apo-Hb dimers are degraded
by proteolysis and harmlessly cleared from circulation. To test the effect of the novel complex we have
planed a range of proof-of-concept studies in animal models of on pump CPB to define the ability of apo-
Hb-haptoglobin dosing to prevent end organ injury.
项目摘要
使用医疗辅助设备后CNS、肺、心脏和肾脏并发症的成本估计
需要血液泵,例如泵式心肺转流术(CPB),
在美国的各个州,在十年的时间里。由于需要延长CPB(> 4小时),
复杂的手术,溶血,以及随后释放的血红蛋白(Hb)进入循环-这是
已知具有多器官毒性和血管活性-是更强化管理的相关因素,
患者迄今为止,没有有效的策略来去除Hb的有毒副产物。造成的负担
仅肾损伤就占约90亿美元/年,30万人死亡/年,
住院时间增加3.5天/患者本项目侧重于了解
持续泵上后溶血、Hb和血红素与继发性终末器官损伤相关
体外循环(通常持续长达4小时)。了解医疗器械相关红细胞
在这种情况下,我们提出了一个战略,重点是顺序理解的贡献,
血红蛋白和血红素以及减轻这些毒素的终末器官病理生理学的治疗策略。我们将
前瞻性地测定Hb、血红素和铁的水平以及每种毒素的浓度,
心脏手术患者的血浆和尿液。同时,我们将确定
血红蛋白、血红素和铁结合和清除蛋白、触珠蛋白、血红素结合蛋白和转铁蛋白。
此外,我们将确定终末器官损伤的血浆和尿液标记物。我们将使用这些数据来构建
确定与终末器官损伤相关的Hb毒素浓度限值的生物动力学模型
标记。这项工作的目标是确定治疗干预的需要和时机。本
最后,根据我们丰富的经验,我们已经生物工程化了一种新的血红蛋白,血红素和蛋白质清除剂
研究Hb毒性。该新型蛋白质构建体通过在多步过程中产生apo-Hb来制备,
同时从科恩分级糊IV中分离触珠蛋白。最后,这两种蛋白质是
复合并进一步纯化以产生apo-Hb-触珠蛋白复合物。这种新的蛋白质结构
在高血红素暴露状态下结合血红素,将铁固定在血红素配体中,并安全地清除复合物,
单核细胞和巨噬细胞。或者,在高Hb暴露下,apo-Hb交换了
结合珠蛋白将Hb二聚体清除到单核细胞和巨噬细胞,而释放的apo-Hb二聚体被降解
通过蛋白水解无害地从循环中清除。为了测试我们的小说情结的效果,
计划在体外循环的动物模型中进行一系列概念验证研究,以确定apo的能力,
Hb-触珠蛋白给药以防止终末器官损伤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Werner Buehler其他文献
Paul Werner Buehler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Werner Buehler', 18)}}的其他基金
The paradoxical response to iron in pulmonary hypertension of sickle cell disease
镰状细胞病肺动脉高压对铁的矛盾反应
- 批准号:
10340518 - 财政年份:2022
- 资助金额:
$ 70.2万 - 项目类别:
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis
生物工程新型治疗性蛋白质复合物可最大程度地减少医疗设备引起的溶血的影响
- 批准号:
10542403 - 财政年份:2022
- 资助金额:
$ 70.2万 - 项目类别:
The paradoxical response to iron in pulmonary hypertension of sickle cell disease
镰状细胞病肺动脉高压对铁的矛盾反应
- 批准号:
10553099 - 财政年份:2022
- 资助金额:
$ 70.2万 - 项目类别:
Engineering a novel biomaterial for oxygen transport applications
设计用于氧传输应用的新型生物材料
- 批准号:
10545751 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin
生物工程双功能蛋白质结构以解毒血红素和血红蛋白
- 批准号:
10437908 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin
生物工程双功能蛋白质结构以解毒血红素和血红蛋白
- 批准号:
10308814 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
Engineering a novel biomaterial for oxygen transport applications
设计用于氧传输应用的新型生物材料
- 批准号:
10322431 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin
生物工程双功能蛋白质结构以解毒血红素和血红蛋白
- 批准号:
10663258 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases
溶血性疾病治疗中血红蛋白毒性的雾化治疗
- 批准号:
10374485 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases
溶血性疾病治疗中血红蛋白毒性的雾化治疗
- 批准号:
10531919 - 财政年份:2021
- 资助金额:
$ 70.2万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 70.2万 - 项目类别:
Continuing Grant